Leerink Partnrs Has Negative Estimate for A Q3 Earnings

Agilent Technologies, Inc. (NYSE:A - Free Report) - Analysts at Leerink Partnrs reduced their Q3 2025 earnings estimates for shares of Agilent Technologies in a research report issued to clients and investors on Thursday, May 29th. Leerink Partnrs analyst P. Souda now anticipates that the medical research company will post earnings of $1.37 per share for the quarter, down from their previous estimate of $1.40. The consensus estimate for Agilent Technologies' current full-year earnings is $5.58 per share.

A has been the topic of several other research reports. TD Cowen lifted their target price on shares of Agilent Technologies to $150.00 and gave the company a "buy" rating in a report on Thursday, May 29th. Robert W. Baird decreased their target price on shares of Agilent Technologies from $159.00 to $140.00 and set an "outperform" rating on the stock in a research report on Thursday, May 22nd. Leerink Partners boosted their price objective on shares of Agilent Technologies to $135.00 and gave the stock a "buy" rating in a research report on Friday. Barclays reduced their price target on shares of Agilent Technologies from $138.00 to $115.00 and set an "equal weight" rating on the stock in a report on Thursday, April 10th. Finally, Wells Fargo & Company reduced their target price on Agilent Technologies from $155.00 to $135.00 and set an "overweight" rating on the stock in a research note on Thursday, April 17th. Seven research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company's stock. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $140.15.

Agilent Technologies Stock Performance

Shares of A stock traded up $1.68 during mid-day trading on Friday, hitting $112.73. 463,144 shares of the stock were exchanged, compared to its average volume of 2,081,967. Agilent Technologies has a 12-month low of $96.43 and a 12-month high of $153.84. The company has a debt-to-equity ratio of 0.55, a quick ratio of 1.60 and a current ratio of 2.09. The stock has a market capitalization of $32.14 billion, a price-to-earnings ratio of 27.83, a P/E/G ratio of 3.40 and a beta of 1.23. The stock's fifty day simple moving average is $108.27 and its two-hundred day simple moving average is $126.27.

Agilent Technologies (NYSE:A - Get Free Report) last posted its quarterly earnings data on Wednesday, May 28th. The medical research company reported $1.31 earnings per share for the quarter, topping analysts' consensus estimates of $1.26 by $0.05. Agilent Technologies had a return on equity of 25.92% and a net margin of 17.59%. The business had revenue of $1.67 billion for the quarter, compared to analyst estimates of $1.63 billion. During the same quarter in the prior year, the company earned $1.22 earnings per share. The company's revenue was up 6.0% on a year-over-year basis.

Hedge Funds Weigh In On Agilent Technologies

A number of institutional investors and hedge funds have recently added to or reduced their stakes in A. Sienna Gestion boosted its position in Agilent Technologies by 29.8% during the 4th quarter. Sienna Gestion now owns 78,445 shares of the medical research company's stock worth $10,537,000 after acquiring an additional 17,991 shares during the period. Sequoia Financial Advisors LLC lifted its position in shares of Agilent Technologies by 8.5% in the fourth quarter. Sequoia Financial Advisors LLC now owns 33,898 shares of the medical research company's stock worth $4,554,000 after buying an additional 2,664 shares during the last quarter. Prudential PLC lifted its position in shares of Agilent Technologies by 16.0% in the fourth quarter. Prudential PLC now owns 73,273 shares of the medical research company's stock worth $9,843,000 after buying an additional 10,128 shares during the last quarter. Commonwealth Equity Services LLC lifted its position in shares of Agilent Technologies by 9.8% in the fourth quarter. Commonwealth Equity Services LLC now owns 43,862 shares of the medical research company's stock worth $5,892,000 after buying an additional 3,915 shares during the last quarter. Finally, Daiwa Securities Group Inc. lifted its holdings in Agilent Technologies by 16.0% in the 4th quarter. Daiwa Securities Group Inc. now owns 49,288 shares of the medical research company's stock worth $6,621,000 after purchasing an additional 6,802 shares during the last quarter.

Insider Activity at Agilent Technologies

In other news, VP Rodney Gonsalves sold 1,908 shares of the stock in a transaction that occurred on Monday, March 17th. The shares were sold at an average price of $121.98, for a total value of $232,737.84. Following the completion of the transaction, the vice president now directly owns 21,786 shares in the company, valued at $2,657,456.28. This trade represents a 8.05% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Daniel K. Podolsky sold 1,819 shares of the stock in a transaction that occurred on Monday, March 31st. The shares were sold at an average price of $116.46, for a total transaction of $211,840.74. Following the completion of the transaction, the director now owns 35,737 shares of the company's stock, valued at $4,161,931.02. This trade represents a 4.84% decrease in their ownership of the stock. The disclosure for this sale can be found here.

Agilent Technologies Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, July 23rd. Investors of record on Tuesday, July 1st will be given a dividend of $0.248 per share. This represents a $0.99 dividend on an annualized basis and a dividend yield of 0.88%. The ex-dividend date of this dividend is Tuesday, July 1st. Agilent Technologies's dividend payout ratio is presently 24.44%.

Agilent Technologies Company Profile

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.